Hyperammonemia Clinical Trial
Official title:
A Phase 1b/2a, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Multiple Ascending Doses of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05842837 -
A Non-Interventional Post-Authorization Study of Carbaglu for the Treatment of Hyperammonemia Due to MMA and PA
|
||
Terminated |
NCT05349435 -
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
|
Phase 1 | |
Completed |
NCT03947034 -
Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
|
||
Completed |
NCT06178718 -
A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules
|
Phase 1 | |
Recruiting |
NCT05040178 -
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
|
||
Withdrawn |
NCT00279851 -
Blood Sugars in Children With Idiopathic Seizures.
|